• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Sarah Faulkner

Delcath registers $10m offering

April 10, 2018 By Sarah Faulkner

Delcath Systems

Delcath Systems (NSDQ:DCTH) proposed offering up to $5 million in units and $5 million in pre-funded units this week to fund the company’s clinical and commercial operations. The New York-based company plans to offer 500,000,000 units made up of Series C units with one share of common stock and Series E warrants to buy one share […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Delcath Systems Inc.

How CHF Solutions is using health economics to expand product adoption

April 10, 2018 By Sarah Faulkner

Two years after CHF Solutions (NSDQ:CHFS) acquired Baxter‘s (NYSE:BAX) Aquadex fluid filtration device for $5 million, the company’s executives are working to weave together the evidence they need to land reimbursement in the U.S. and expand patient access for its technology. The Aquadex system is designed to filter water and salt from patients experiencing fluid overload due […]

Filed Under: Cardiovascular, Featured, Wall Street Beat Tagged With: Baxter, chfsolutions, devicetalksminnesota

Illumina, Loxo Oncology partner for next-gen pan-cancer companion diagnostics

April 10, 2018 By Sarah Faulkner

Illumina

Illumina (NSDQ:ILMN) and Loxo Oncology (NSDQ:LOXO) are teaming up to develop a multi-gene panel for broad tumor profiling. The two companies ultimately hope to sell a next-gen sequencing-based companion diagnostic that will boast a pan-cancer indication. Illumina and Loxo plan to seek approval for a version of Illumina’s TruSight Tumor 170 test as a companion […]

Filed Under: Diagnostics, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: illumina, loxooncology

Delcath approves massive reverse split

April 9, 2018 By Sarah Faulkner

Delcath Systems

Delcath Systems (NSDQ:DCTH) said today that shareholders approved a bid to increase the company’s authorized shares of common stock from 500,000,000 to 1,000,000,000. The New York-based oncology group also voted to effect a reverse stock split of Delcath’s common stock at a range of 1-for-100 to 1-for-500. The board of directors have until April 6, 2019 […]

Filed Under: Drug-Device Combinations, Featured, Oncology, Wall Street Beat Tagged With: Delcath Systems Inc.

Companies push back against allegations of FCA violations over excess at-home blood testing

April 9, 2018 By Sarah Faulkner

gavel

A 70-year-old former Marine is taking a group of companies to court over their at-home blood testing services, arguing that the industry players broke the law by requiring patients to conduct weekly tests. The companies then submit these bills to Medicare for reimbursement, even asking to be repaid for services that weren’t rendered, according to […]

Filed Under: Cardiovascular, Diagnostics, Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: advancedcardioservices, alere, cardiolink, mdinr, patienthomemonitoring, Roche, ushealthcaresupply

Tandem inks distro deal in Italy for insulin pump

April 9, 2018 By Sarah Faulkner

Tandem Diabetes

Tandem Diabetes Care (NSDQ:TNDM) has signed a distribution deal with Movi SpA to commercialize Tandem’s t:slim X2 insulin pump in Italy. The San Diego, Calif.-based company said today that Movi is slated to run sales, marketing and customer training for Tandem’s products in Italy, according to the terms of the agreement. “Partnering with experienced insulin pump […]

Filed Under: Diabetes, Distribution, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Tandem Diabetes Care

Manufacturing fault prompts BD to recall blood collection tubes

April 9, 2018 By Sarah Faulkner

Becton Dickinson‘s (NYSE: BDX) life sciences division issued a recall last month for some of its blood collection tubes, citing a manufacturing flaw that resulted in devices without sufficient additive. The company explained that an internal investigation found that Vacutainer Citrate Plus tubes with too little additive led to falsely-shortened clotting time and could impact patient […]

Filed Under: Diagnostics, Featured, Recalls, Regulatory/Compliance, Wall Street Beat Tagged With: Becton Dickinson

AstraZeneca taps Owlstone’s breath biopsy device to identify asthma, COPD biomarkers

April 9, 2018 By Sarah Faulkner

Owlstone Medical's breath biopsy device

Pharmaceutical giant AstraZeneca (NYSE:AZN) inked a deal with Owlstone Medical to use the diagnostics company’s breath biopsy device to identify biomarkers for asthma and chronic obstructive pulmonary disease, the companies announced today. Owlstone’s ReCiva breath sampler, which has CE Mark clearance in the E.U., captures volatile organic compounds in a patient’s breath. A VOC profile can […]

Filed Under: Clinical Trials, Diagnostics, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development, Respiratory, Wall Street Beat Tagged With: AstraZeneca plc, GlaxoSmithKline plc, Owlstone Medical

Embolx wins $2m NIH grant for pressure-directed embolization therapy

April 6, 2018 By Sarah Faulkner

Embolx

Embolx said today that it landed a $2 million grant from the National Cancer Institute to fund development of its next-generation Sniper balloon occlusion microcatheter. The Sunnyvale, Calif.-based medical device company has developed a drug-delivery system that administers therapies into targeted areas of the body by controlling pressure. Embolx’s Sniper balloon is designed to treat cancerous […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Oncology, Pharmaceuticals, Research & Development Tagged With: embolx

Study: PET imaging agent could help predict depression drug’s efficacy

April 6, 2018 By Sarah Faulkner

Imaging agent for depression

Researchers have identified a positron emission tomography imaging agent that could identify the patients that are more likely to benefit from a drug designed to treat major depressive disorder, according to a study published this month in The Journal of Nuclear Medicine. The C-DASB tracer targets a protein, 5-HTT, found in the part of a person’s […]

Filed Under: Featured, Imaging, Neurological, Pharmaceuticals Tagged With: National Institutes of Health

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 56
  • Page 57
  • Page 58
  • Page 59
  • Page 60
  • Interim pages omitted …
  • Page 241
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS